LCID
Lucid Group, Inc.
LCID offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
XPEV
XPeng Inc.
XPEV has a slight edge over LCID overall, supported by lower modeled downside and stronger fundamentals.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
XPEV Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Stable | |
| Unavailable |
XPEV's revenue and cash flow are currently stable, but its profitability is under pressure. There isn't enough data to rate its balance sheet.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
XPEV PE Valuation
XPEV has no meaningful PE right now: it lost money over the past year.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
XPEV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect XPEV's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
XPEV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.93 | -$0.25 |
| Q1 2026 | -$0.58 | +$0.23 |
| Q4 2025 | -$0.12 | +$0.80 |
| Q3 2025 | -$0.45 | +$0.47 |
| Q2 2025 | -$0.68 | +$0.63 |
| Q1 2025 | -$0.81 | +$0.79 |
| Q4 2024 | -$0.92 | +$0.87 |
| Q3 2024 | -$0.92 | +$1.07 |
XPEV has the edge over LCID on earnings, with more consistent year-over-year improvement.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over XPEV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
XPEV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3B | +7.7% |
| Q1 2026 | $1.9B | -18% |
| Q4 2025 | $3.3B | +36% |
| Q3 2025 | $3.1B | +102% |
| Q2 2025 | $2.7B | +125% |
| Q1 2025 | $2.4B | +141% |
| Q4 2024 | $2.4B | +23% |
| Q3 2024 | $1.5B | +18% |
XPEV's revenue is growing: $3B last quarter, up 7.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -6.7% | -1.6 points |
| Q1 2026 | -16% | -9.6 points |
| Q4 2025 | -4.2% | +5.5 points |
| Q3 2025 | -3.7% | +15 points |
| Q2 2025 | -5.1% | +15 points |
| Q1 2025 | -6.6% | +19 points |
| Q4 2024 | -9.7% | +6.1 points |
| Q3 2024 | -18% | +19 points |
XPEV has the edge over LCID on profitability, with a higher operating margin.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has the edge over XPEV on cash flow, with more consistent year-over-year improvement.
XPEV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | $0 |
| Q1 2026 | $0 | $0 |
| Q4 2025 | $0 | $0 |
| Q3 2025 | $0 | $0 |
| Q2 2025 | $0 | $0 |
| Q1 2025 | $0 | $0 |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
XPEV's free cash flow was $0 over the past year, against $0 the year before.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
XPEV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +541K shares |
| 1 year | -49% | -467M shares |
| 3 years | -45% | -383M shares |
| 5 years | -44% | -377M shares |
| Available history | -44% | -377M shares |
XPEV has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
XPEV hasn't bought back shares in the past year.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
XPEV Net Leverage
XPEV's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
XPEV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.5 | Neutral |
| Stochastic | 17.7 | Oversold |
XPEV's weekly RSI is 36 (neutral) and its Stochastic is 18 (oversold).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
XPEV PE vs Consumer Cyclical Sector
XPEV has no meaningful PE right now: it lost money over the past year.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
XPEV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.56 | 1% below |
| 20 week MA | $11.1 | 14% below |
| 50 week MA | $14.9 | 37% below |
| 100 week MA | $17.2 | 45% below |
| 200 week MA | $14.2 | 33% below |
XPEV is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
XPEV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.8 | $41.9 | +84% |
| 2021 | $41.9 | $46.1 | +10% |
| 2022 | $46.1 | $10.1 | -78% |
| 2023 | $10.1 | $14.6 | +45% |
| 2024 | $14.6 | $12.6 | -13% |
| 2025 | $12.6 | $20.8 | +65% |
| 2026 YTD | $20.8 | $9.46 | -54% |
XPEV has the edge over LCID on returns for 2026, with the stronger performance.